MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
VolitionRx Limited Market Cap 2011-2026 | VNRX
As of March 04, 2026 VolitionRx Limited has a market cap of $ 19.2 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap VolitionRx Limited
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 54.8 M | 58.1 M | 89.1 M | 157 M | 200 M | 185 M | 79.7 M | 92.6 M | 107 M | 66.8 M | 67.2 M | 27.1 M | 23.4 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 200 M | 23.4 M | 92.9 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Anixa Biosciences
ANIX
|
104 K | $ 2.85 | -3.72 % | $ 92.5 K |  USA |
 |
Centogene N.V.
CNTG
|
221 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
42 B | $ 118.6 | 0.4 % | $ 36.1 B | USA |
 |
Celcuity
CELC
|
399 M | $ 107.62 | -0.63 % | $ 4.25 B | USA |
|
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
709 M | $ 27.55 | -1.59 % | $ 765 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M |  Britain |
 |
Charles River Laboratories International
CRL
|
7.69 B | $ 175.77 | -1.61 % | $ 8.71 B | USA |
 |
Fulgent Genetics
FLGT
|
467 M | $ 13.82 | -2.68 % | $ 418 M | USA |
 |
Aspira Women's Health
AWH
|
45.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
40.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
243 M | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
9.22 B | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
1.54 B | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
92.1 M | $ 15.5 | -1.59 % | $ 2.01 B | USA |
 |
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
3.55 M | $ 1.12 | -1.78 % | $ 1.42 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
23.3 B | $ 208.28 | -0.95 % | $ 23.1 B | USA |
 |
Danaher Corporation
DHR
|
150 B | $ 204.04 | -0.9 % | $ 145 B | USA |
 |
Exact Sciences Corporation
EXAS
|
19.5 B | $ 103.38 | 0.02 % | $ 19.5 B | USA |
 |
Bioventus
BVS
|
351 M | $ 8.8 | 0.34 % | $ 551 M | USA |
 |
DarioHealth Corp.
DRIO
|
43.4 M | $ 10.3 | -4.19 % | $ 292 M |  Israel |
 |
DexCom
DXCM
|
25.5 B | $ 73.0 | -1.06 % | $ 28.5 B | USA |
 |
ICON Public Limited Company
ICLR
|
16.6 B | $ 108.44 | 0.16 % | $ 8.94 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
51.1 B | $ 635.29 | -0.22 % | $ 51.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
8.52 B | - | - | $ 10.6 B |  Niderland |
 |
Burning Rock Biotech Limited
BNR
|
2.95 B | $ 24.01 | -4.59 % | $ 254 M | China |
 |
Illumina
ILMN
|
16.4 B | $ 129.9 | -2.25 % | $ 20.7 B | USA |
 |
CareDx, Inc
CDNA
|
993 M | $ 18.74 | -0.03 % | $ 999 M | USA |
 |
Chembio Diagnostics
CEMI
|
12.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
4.33 M | - | - | $ 9.42 M | Israel |
 |
Guardant Health
GH
|
13.4 B | $ 93.21 | 1.06 % | $ 11.7 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
23.9 B | $ 283.19 | -1.07 % | $ 23.6 B | USA |
 |
Lantheus Holdings
LNTH
|
5.12 B | $ 79.15 | 3.74 % | $ 5.34 B | USA |
 |
IQVIA Holdings
IQV
|
28.3 B | $ 174.33 | 0.03 % | $ 30 B | USA |
 |
Brainsway Ltd.
BWAY
|
240 M | $ 23.2 | -2.09 % | $ 99.4 M | Israel |
 |
Co-Diagnostics
CODX
|
34.9 M | - | - | $ 79.8 M | USA |
 |
Mettler-Toledo International
MTD
|
28.4 B | $ 1 315.61 | -0.56 % | $ 27.1 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
409 M | $ 5.26 | 4.89 % | $ 487 M | USA |
 |
NeoGenomics
NEO
|
1.48 B | $ 9.53 | 0.26 % | $ 1.22 B | USA |
 |
DermTech
DMTK
|
42.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
Natera
NTRA
|
5.31 B | $ 206.39 | 3.11 % | $ 20.3 B | USA |
 |
Enzo Biochem
ENZ
|
57.5 K | - | -8.98 % | $ 14.8 K | USA |
 |
Pacific Biosciences of California
PACB
|
498 M | $ 1.51 | -7.1 % | $ 453 M | USA |
 |
Neogen Corporation
NEOG
|
1.02 B | $ 10.93 | -1.97 % | $ 2.37 B | USA |
 |
Precipio
PRPO
|
8.7 M | $ 24.78 | 0.38 % | $ 32.2 M | USA |
 |
Heska Corporation
HSKA
|
844 M | - | - | $ 1.31 B | USA |